Genscript USA Inc.

Genscript USA Inc., a for-profit biotechnology company headquartered in Piscataway, New Jersey, supplies gene synthesis, protein production, antibody development, and cell line engineering services to federal life sciences research agencies as a prime contractor on a full-and-open, non-set-aside basis. The vendor operates entirely in the prime role across a 606-award footprint spanning 2010 to August 2026, with no subcontractor presence.

Genscript's customer base is heavily concentrated in the Department of Health and Human Services research ecosystem. The National Institute of Allergy and Infectious Diseases leads by award count (156 awards, $9.9 million combined potential value) and the National Cancer Institute anchors the dollar ranking (142 awards, $10.2 million), together accounting for roughly 50% of recent awards. The FDA, National Institute of Child Health and Human Development, CDC Pittsburgh, and the Department of Agriculture round out the top tier, with NIAID and NCI dominating both volume and dollars. Across the top five customer agencies, the vendor serves 70% of award activity.

Genscript operates under multiple blanket purchase agreements and indefinite delivery vehicles. The largest parent vehicle is HHSN261201500015I (an NIH IDC) carrying 64 task orders worth $438 thousand combined, followed by HHSN263201400039B (a second NIH BPA) with 44 task orders worth $519 thousand. A USDA Animal and Plant Health Inspection Service BPA (12639522A0017) for SARS-CoV-2 surrogate virus neutralization test kits represents a single $1.5 million vehicle with six task orders totaling $841 thousand. Representative recent work includes a $4.1 million National Cancer Institute purchase order (awarded September 2024, completion September 2027) for synthesis services for custom biomolecules in support of mutation-reactive T cell detection; a $702,500 NIAID sole-source purchase order (April 2022 through September 2024) for SARS-CoV-2 variant gene synthesis supporting COVID-19 therapeutics and vaccine testing; and a $249,243.54 NIAID gene production and protein expression contract (August 2023 through August 2024) for gene synthesis, cloning, plasmid preparation, and protein purification.

Activity has declined materially from peak levels: 45 awards in 2023 and 39 in 2022 dropped to 23 in 2024, 8 in 2025, and 1 in 2026 year-to-date. Four awards carrying combined potential value of $5.5 million face ultimate completion within the next twenty-four months, presenting moderate recompete exposure.

SCI reporting covers only five prime service contracts above the $150,000 threshold across fiscal years 2022–2024, capturing $906 thousand in invoiced revenue and 26.4 FTEs in FY2022 only; subsequent years show zero SCI-reportable activity, likely reflecting a shift toward lower-threshold purchase orders and micro-purchases that fall outside SCI's $150,000 reporting floor. Government-paid hourly rates on SCI-reportable contracts ranged from $3.64/hr (tenth percentile) to $32.77/hr (ninetieth percentile), with median around $18.20/hr. The vendor performs all work with internal staff; across SCI-reportable primes, subcontractor hours represent zero share of total delivery.

Genscript's federal posture centers on life sciences research support for NIH institutes, CDC, and USDA, with no material presence in defense, civilian IT, or construction sectors. The vendor competes entirely in full-and-open procurements with no SBA set-aside activity across its footprint, positioning it as a commercial-market biotech vendor rather than a small-business incumbent.